Breaking Down SG&A Expenses: Biogen Inc. vs Lantheus Holdings, Inc.

A Comparative Analysis of SG&A Expenses: Biogen Inc. vs. Lantheus Holdings, Inc.

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial dynamics of key players is crucial. Over the past decade, Biogen Inc. and Lantheus Holdings, Inc. have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Biogen's SG&A expenses have shown a steady increase, peaking in 2021 with a 38% rise from 2014. In contrast, Lantheus Holdings, Inc. has experienced a more dramatic growth, with expenses surging by over 270% during the same period. This stark difference highlights the varying strategic approaches of these companies in managing operational costs. While Biogen's expenses reflect a more stable growth, Lantheus's significant increase suggests aggressive expansion and investment in administrative capabilities. As the industry continues to evolve, these financial strategies will play a pivotal role in shaping the future trajectories of these companies.